FDA launches adverse event look-up tool

Silver Spring, Maryland — The U.S. Food and Drug Administration says it has launched a unified platform for collecting and analyzing adverse event reports across regulated product categories, with a public dashboard intended to expand access to safety reporting data while stressing key limits in what those reports can prove. We confirmed the core facts across six reachable sources: FDA news release, FDA AEMS public dashboard, FDA AEMS overview, BeautyMatter, SafetyCall, and Drug and Device Law Blog. Each of the bullet points immediately below have been confirmed by at least four of the six respected sources we curated on this story.

Core Facts

• The FDA says it has launched the FDA Adverse Event Monitoring System, known as AEMS.
• AEMS consolidates multiple adverse event reporting databases that previously operated separately across product categories.
• The platform includes a public dashboard for searching adverse event reports, and the FDA emphasizes that a report does not establish causation or confirm accuracy.
• The FDA says additional reporting systems, including those covering medical devices, foods and dietary supplements, and tobacco products, are slated for integration later this spring.
• FDA documentation describes AEMS as a centralized intake platform that also supports handling certain consumer complaints and misconduct reports.

Additional Details Reported

Agency materials describe the new platform as part of a broader modernization effort focused on standardizing reporting, improving internal processing, and strengthening cross-product safety surveillance through updated workflows and analytics.

Across the documentation and outside analysis, the most prominent caution is interpretive: adverse event reports can be incomplete or duplicative, and the existence of a report alone does not prove that a product caused a health outcome.

How we report: We select the day’s most important stories, confirm facts across multiple reputable sources, and avoid anonymous sourcing. Our goal is clear, balanced coverage you can trust—because transparency and verification matter for informed readers.